https://hemonc.org/w/api.php?hidebots=1&urlversion=1&days=7&limit=50&target=Anastrozole_%28Arimidex%29&action=feedrecentchanges&feedformat=atom
HemOnc.org - A Hematology Oncology Wiki - Changes related to "Anastrozole (Arimidex)" [en]
2024-03-29T14:12:18Z
Related changes
MediaWiki 1.35.14
https://hemonc.org/w/index.php?title=Breast_cancer&diff=84516&oldid=84335
Breast cancer
2024-03-26T00:31:16Z
<p><span dir="auto"><span class="autocomment">Metastatic disease, subsequent lines of chemotherapy</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 00:31, 26 March 2024</td>
</tr><tr><td colspan="4" class="diff-multi" lang="en">(One intermediate revision by the same user not shown)</td></tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l2886" >Line 2,886:</td>
<td colspan="2" class="diff-lineno">Line 2,886:</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584474/ Mavroudis et al. 2017 (HORG CT/01.04)]</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584474/ Mavroudis et al. 2017 (HORG CT/01.04)]</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|2001-2013</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|2001-2013</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9851" |Phase 3 (<del class="diffchange diffchange-inline">E-switch-ic</del>)</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9851" |Phase 3 (<ins class="diffchange diffchange-inline">C</ins>)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|[[#Epirubicin_.26_Docetaxel_999|Epirubicin & Docetaxel]]</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|[[#Epirubicin_.26_Docetaxel_999|Epirubicin & Docetaxel]]</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#d9ef8b" |Might have superior DFS (primary endpoint)<br>DFS60: 92.6% vs 88.2%<br>(HR 0.63, 95% CI 0.39-1.01)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#d9ef8b" |Might have superior DFS (primary endpoint)<br>DFS60: 92.6% vs 88.2%<br>(HR 0.63, 95% CI 0.39-1.01)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|}</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|}</div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">''Note: to our knowledge, this regimen variant was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.''</ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><div class="toccolours" style="background-color:#cbd5e8"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><div class="toccolours" style="background-color:#cbd5e8"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>====Preceding treatment====</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>====Preceding treatment====</div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l2902" >Line 2,902:</td>
<td colspan="2" class="diff-lineno">Line 2,903:</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>'''21-day cycle for 8 cycles (E x 4; D x 4)'''</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>'''21-day cycle for 8 cycles (E x 4; D x 4)'''</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div></div></div></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div></div></div></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"></ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>===References===</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>===References===</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><!-- Presented at the 46th Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL. --></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><!-- Presented at the 46th Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL. --></div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l10915" >Line 10,915:</td>
<td colspan="2" class="diff-lineno">Line 10,917:</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|2006-2008</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|2006-2008</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9851" |Phase 3 (E-esc)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9851" |Phase 3 (E-esc)</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>|1a. [[#Capecitabine_monotherapy_3|Capecitabine]]<br>1b. [[#Docetaxel_monotherapy_3|Docetaxel]]<br>1c. [[#Gemcitabine_monotherapy_2|Gemcitabine]]<br>1d. [[#Paclitaxel_monotherapy.2C_weekly_3|Paclitaxel]]<br>1e. [[#nab-Paclitaxel_monotherapy_3|nab-Paclitaxel]]<br>1f. [[#<del class="diffchange diffchange-inline">Vinorelbine_monotherapy_2</del>|Vinorelbine]]</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>|1a. [[#Capecitabine_monotherapy_3|Capecitabine]]<br>1b. [[#Docetaxel_monotherapy_3|Docetaxel]]<br>1c. [[#Gemcitabine_monotherapy_2|Gemcitabine]]<br>1d. [[#Paclitaxel_monotherapy.2C_weekly_3|Paclitaxel]]<br>1e. [[#nab-Paclitaxel_monotherapy_3|nab-Paclitaxel]]<br>1f. [[#<ins class="diffchange diffchange-inline">Vinorelbine_monotherapy</ins>|Vinorelbine]]</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 7.2 vs 5.1 mo<br>(HR 0.78, 95% CI 0.64-0.93)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 7.2 vs 5.1 mo<br>(HR 0.78, 95% CI 0.64-0.93)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l11544" >Line 11,544:</td>
<td colspan="2" class="diff-lineno">Line 11,546:</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|2006-2008</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|2006-2008</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9851" |Phase 3 (E-esc)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9851" |Phase 3 (E-esc)</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>|1a. [[#Capecitabine_monotherapy_3|Capecitabine]]<br>1b. [[#Docetaxel_monotherapy_3|Docetaxel]]<br>1c. [[#Gemcitabine_monotherapy_2|Gemcitabine]]<br>1d. [[#Paclitaxel_monotherapy.2C_weekly_3|Paclitaxel]]<br>1e. [[#nab-Paclitaxel_monotherapy_3|nab-Paclitaxel]]<br>1f. [[#<del class="diffchange diffchange-inline">Vinorelbine_monotherapy_2</del>|Vinorelbine]]</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>|1a. [[#Capecitabine_monotherapy_3|Capecitabine]]<br>1b. [[#Docetaxel_monotherapy_3|Docetaxel]]<br>1c. [[#Gemcitabine_monotherapy_2|Gemcitabine]]<br>1d. [[#Paclitaxel_monotherapy.2C_weekly_3|Paclitaxel]]<br>1e. [[#nab-Paclitaxel_monotherapy_3|nab-Paclitaxel]]<br>1f. [[#<ins class="diffchange diffchange-inline">Vinorelbine_monotherapy</ins>|Vinorelbine]]</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 7.2 vs 5.1 mo<br>(HR 0.78, 95% CI 0.64-0.93)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 7.2 vs 5.1 mo<br>(HR 0.78, 95% CI 0.64-0.93)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l11574" >Line 11,574:</td>
<td colspan="2" class="diff-lineno">Line 11,576:</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|2006-2008</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|2006-2008</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9851" |Phase 3 (E-esc)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9851" |Phase 3 (E-esc)</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>|1a. [[#Capecitabine_monotherapy_3|Capecitabine]]<br>1b. [[#Docetaxel_monotherapy_3|Docetaxel]]<br>1c. [[#Gemcitabine_monotherapy_2|Gemcitabine]]<br>1d. [[#Paclitaxel_monotherapy.2C_weekly_3|Paclitaxel]]<br>1e. [[#nab-Paclitaxel_monotherapy_3|nab-Paclitaxel]]<br>1f. [[#<del class="diffchange diffchange-inline">Vinorelbine_monotherapy_2</del>|Vinorelbine]]</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>|1a. [[#Capecitabine_monotherapy_3|Capecitabine]]<br>1b. [[#Docetaxel_monotherapy_3|Docetaxel]]<br>1c. [[#Gemcitabine_monotherapy_2|Gemcitabine]]<br>1d. [[#Paclitaxel_monotherapy.2C_weekly_3|Paclitaxel]]<br>1e. [[#nab-Paclitaxel_monotherapy_3|nab-Paclitaxel]]<br>1f. [[#<ins class="diffchange diffchange-inline">Vinorelbine_monotherapy</ins>|Vinorelbine]]</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 7.2 vs 5.1 mo<br>(HR 0.78, 95% CI 0.64-0.93)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 7.2 vs 5.1 mo<br>(HR 0.78, 95% CI 0.64-0.93)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l11902" >Line 11,902:</td>
<td colspan="2" class="diff-lineno">Line 11,904:</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|2013-2015</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|2013-2015</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9851" |Phase 3 (E-switch-ic)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9851" |Phase 3 (E-switch-ic)</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>|[[#<del class="diffchange diffchange-inline">Vinorelbine_monotherapy_2</del>|Vinorelbine]]</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>|[[#<ins class="diffchange diffchange-inline">Vinorelbine_monotherapy</ins>|Vinorelbine]]</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#91cf60" |Seems to have superior PFS (primary endpoint)<br>Median PFS: 2.8 vs 2.8 mo<br>(HR 0.80, 95% CI 0.65-0.98)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#91cf60" |Seems to have superior PFS (primary endpoint)<br>Median PFS: 2.8 vs 2.8 mo<br>(HR 0.80, 95% CI 0.65-0.98)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l12096" >Line 12,096:</td>
<td colspan="2" class="diff-lineno">Line 12,098:</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|2006-2008</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|2006-2008</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9851" |Phase 3 (E-esc)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9851" |Phase 3 (E-esc)</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>|1a. [[#Capecitabine_monotherapy_3|Capecitabine]]<br>1b. [[#Docetaxel_monotherapy_3|Docetaxel]]<br>1c. [[#Gemcitabine_monotherapy_2|Gemcitabine]]<br>1d. [[#Paclitaxel_monotherapy.2C_weekly_3|Paclitaxel]]<br>1e. [[#nab-Paclitaxel_monotherapy_3|nab-Paclitaxel]]<br>1f. [[#<del class="diffchange diffchange-inline">Vinorelbine_monotherapy_2</del>|Vinorelbine]]</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>|1a. [[#Capecitabine_monotherapy_3|Capecitabine]]<br>1b. [[#Docetaxel_monotherapy_3|Docetaxel]]<br>1c. [[#Gemcitabine_monotherapy_2|Gemcitabine]]<br>1d. [[#Paclitaxel_monotherapy.2C_weekly_3|Paclitaxel]]<br>1e. [[#nab-Paclitaxel_monotherapy_3|nab-Paclitaxel]]<br>1f. [[#<ins class="diffchange diffchange-inline">Vinorelbine_monotherapy</ins>|Vinorelbine]]</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 7.2 vs 5.1 mo<br>(HR 0.78, 95% CI 0.64-0.93)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 7.2 vs 5.1 mo<br>(HR 0.78, 95% CI 0.64-0.93)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l12396" >Line 12,396:</td>
<td colspan="2" class="diff-lineno">Line 12,398:</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|2006-2008</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|2006-2008</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9851" |Phase 3 (E-esc)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9851" |Phase 3 (E-esc)</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>|1a. [[#Capecitabine_monotherapy_3|Capecitabine]]<br>1b. [[#Docetaxel_monotherapy_3|Docetaxel]]<br>1c. [[#Gemcitabine_monotherapy_2|Gemcitabine]]<br>1d. [[#Paclitaxel_monotherapy.2C_weekly_3|Paclitaxel]]<br>1e. [[#nab-Paclitaxel_monotherapy_3|nab-Paclitaxel]]<br>1f. [[#<del class="diffchange diffchange-inline">Vinorelbine_monotherapy_2</del>|Vinorelbine]]</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>|1a. [[#Capecitabine_monotherapy_3|Capecitabine]]<br>1b. [[#Docetaxel_monotherapy_3|Docetaxel]]<br>1c. [[#Gemcitabine_monotherapy_2|Gemcitabine]]<br>1d. [[#Paclitaxel_monotherapy.2C_weekly_3|Paclitaxel]]<br>1e. [[#nab-Paclitaxel_monotherapy_3|nab-Paclitaxel]]<br>1f. [[#<ins class="diffchange diffchange-inline">Vinorelbine_monotherapy</ins>|Vinorelbine]]</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 7.2 vs 5.1 mo<br>(HR 0.78, 95% CI 0.64-0.93)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 7.2 vs 5.1 mo<br>(HR 0.78, 95% CI 0.64-0.93)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l12419" >Line 12,419:</td>
<td colspan="2" class="diff-lineno">Line 12,421:</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|2006-2008</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|2006-2008</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9851" |Phase 3 (E-esc)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9851" |Phase 3 (E-esc)</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>|1a. [[#Capecitabine_monotherapy_3|Capecitabine]]<br>1b. [[#Docetaxel_monotherapy_3|Docetaxel]]<br>1c. [[#Gemcitabine_monotherapy_2|Gemcitabine]]<br>1d. [[#Paclitaxel_monotherapy.2C_weekly_3|Paclitaxel]]<br>1e. [[#nab-Paclitaxel_monotherapy_3|nab-Paclitaxel]]<br>1f. [[#<del class="diffchange diffchange-inline">Vinorelbine_monotherapy_2</del>|Vinorelbine]]</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>|1a. [[#Capecitabine_monotherapy_3|Capecitabine]]<br>1b. [[#Docetaxel_monotherapy_3|Docetaxel]]<br>1c. [[#Gemcitabine_monotherapy_2|Gemcitabine]]<br>1d. [[#Paclitaxel_monotherapy.2C_weekly_3|Paclitaxel]]<br>1e. [[#nab-Paclitaxel_monotherapy_3|nab-Paclitaxel]]<br>1f. [[#<ins class="diffchange diffchange-inline">Vinorelbine_monotherapy</ins>|Vinorelbine]]</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 7.2 vs 5.1 mo<br>(HR 0.78, 95% CI 0.64-0.93)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 7.2 vs 5.1 mo<br>(HR 0.78, 95% CI 0.64-0.93)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l12611" >Line 12,611:</td>
<td colspan="2" class="diff-lineno">Line 12,613:</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|2006-2008</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|2006-2008</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9851" |Phase 3 (E-esc)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9851" |Phase 3 (E-esc)</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>|1a. [[#Capecitabine_monotherapy_3|Capecitabine]]<br>1b. [[#Docetaxel_monotherapy_3|Docetaxel]]<br>1c. [[#Gemcitabine_monotherapy_2|Gemcitabine]]<br>1d. [[#Paclitaxel_monotherapy.2C_weekly_3|Paclitaxel]]<br>1e. [[#nab-Paclitaxel_monotherapy_3|nab-Paclitaxel]]<br>1f. [[#<del class="diffchange diffchange-inline">Vinorelbine_monotherapy_2</del>|Vinorelbine]]</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>|1a. [[#Capecitabine_monotherapy_3|Capecitabine]]<br>1b. [[#Docetaxel_monotherapy_3|Docetaxel]]<br>1c. [[#Gemcitabine_monotherapy_2|Gemcitabine]]<br>1d. [[#Paclitaxel_monotherapy.2C_weekly_3|Paclitaxel]]<br>1e. [[#nab-Paclitaxel_monotherapy_3|nab-Paclitaxel]]<br>1f. [[#<ins class="diffchange diffchange-inline">Vinorelbine_monotherapy</ins>|Vinorelbine]]</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 7.2 vs 5.1 mo<br>(HR 0.78, 95% CI 0.64-0.93)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 7.2 vs 5.1 mo<br>(HR 0.78, 95% CI 0.64-0.93)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l12669" >Line 12,669:</td>
<td colspan="2" class="diff-lineno">Line 12,671:</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|NR</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|NR</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9851" |Phase 3 (E-switch-ic)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9851" |Phase 3 (E-switch-ic)</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>|1. [[#Mitomycine_.26_Vinblastine_888|Mitomycin & Vinblastine]]<br>2. [[#<del class="diffchange diffchange-inline">Vinorelbine_monotherapy_2</del>|Vinorelbine]]</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>|1. [[#Mitomycine_.26_Vinblastine_888|Mitomycin & Vinblastine]]<br>2. [[#<ins class="diffchange diffchange-inline">Vinorelbine_monotherapy</ins>|Vinorelbine]]</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l12936" >Line 12,936:</td>
<td colspan="2" class="diff-lineno">Line 12,938:</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|2006-2008</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|2006-2008</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9851" |Phase 3 (E-esc)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9851" |Phase 3 (E-esc)</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>|1a. [[#Capecitabine_monotherapy_3|Capecitabine]]<br>1b. [[#Docetaxel_monotherapy_3|Docetaxel]]<br>1c. [[#Gemcitabine_monotherapy_2|Gemcitabine]]<br>1d. [[#Paclitaxel_monotherapy.2C_weekly_3|Paclitaxel]]<br>1e. [[#nab-Paclitaxel_monotherapy_3|nab-Paclitaxel]]<br>1f. [[#<del class="diffchange diffchange-inline">Vinorelbine_monotherapy_2</del>|Vinorelbine]]</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>|1a. [[#Capecitabine_monotherapy_3|Capecitabine]]<br>1b. [[#Docetaxel_monotherapy_3|Docetaxel]]<br>1c. [[#Gemcitabine_monotherapy_2|Gemcitabine]]<br>1d. [[#Paclitaxel_monotherapy.2C_weekly_3|Paclitaxel]]<br>1e. [[#nab-Paclitaxel_monotherapy_3|nab-Paclitaxel]]<br>1f. [[#<ins class="diffchange diffchange-inline">Vinorelbine_monotherapy</ins>|Vinorelbine]]</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 7.2 vs 5.1 mo<br>(HR 0.78, 95% CI 0.64-0.93)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 7.2 vs 5.1 mo<br>(HR 0.78, 95% CI 0.64-0.93)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l12951" >Line 12,951:</td>
<td colspan="2" class="diff-lineno">Line 12,953:</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><!-- Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009, and at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010. --></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><!-- Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009, and at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010. --></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div># '''RIBBON-2:''' Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011 Nov 10;29(32):4286-93. Epub 2011 Oct 11. [https://doi.org/10.1200/JCO.2010.34.1255 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21990397/ PubMed] [https://clinicaltrials.gov/study/NCT00281697 NCT00281697]</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div># '''RIBBON-2:''' Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011 Nov 10;29(32):4286-93. Epub 2011 Oct 11. [https://doi.org/10.1200/JCO.2010.34.1255 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21990397/ PubMed] [https://clinicaltrials.gov/study/NCT00281697 NCT00281697]</div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"></ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=Additional resources=</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=Additional resources=</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*[http://www.cancer.gov/bcrisktool/ Gail model Breast Cancer Risk Assessment Tool]</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*[http://www.cancer.gov/bcrisktool/ Gail model Breast Cancer Risk Assessment Tool]</div></td></tr>
<!-- diff cache key onc_dryang_org-wiki_:diff::1.12:old-84335:rev-84516 -->
</table>
Jwarner
https://hemonc.org/w/index.php?title=Endometrial_cancer&diff=84455&oldid=84403
Endometrial cancer
2024-03-23T10:43:01Z
<p></p>
<a href="https://hemonc.org/w/index.php?title=Endometrial_cancer&diff=84455&oldid=84403">Show changes</a>
Jwarner